K-924

K-924 is a potent and highly selective small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), developed by Kowa Company. RIPK1 is a critical mediator of the signaling pathways involved in inflammation and necroptosis, a form of programmed cell death triggered by tumor necrosis factor (TNF) and other pro-inflammatory stimuli. By specifically inhibiting the kinase activity of RIPK1, K-924 prevents the formation of the necrosome complex, thereby blocking necroptotic cell death and the subsequent release of damage-associated molecular patterns (DAMPs) that drive systemic inflammation. Preclinical studies have demonstrated that K-924 has excellent oral bioavailability and significant therapeutic potential in animal models of systemic inflammatory response syndrome (SIRS) and other inflammatory conditions.